Recent posts and comments

• Genzyme Seeks Dual Approval, Google Health Picks Another Massachusetts Partner, Biogen Shareholders To Provide Closure (Maybe), & More Life Science News

  Seems like most of the Massachusetts life sciences industry is out in San Diego at BIO this week—along with Governor Patrick—plugging the newly signed $1 billion funding bill. But... Read more »

• Will CombinatoRx Be the Next Cambridge Biotech Put on the Block?

  Millennium Pharmaceuticals. Sirtris Pharmaceuticals. Maybe Biogen Idec (or maybe not). Will CombinatoRx (NASDAQ:CRXX) be next on the list of Cambridge, MA, biotech firms scooped up... Read more »

• $8 Million for JazzD Markets

  Stealthy online directory firm JazzD Markets of Brookline, MA, completed a $8 million in Series A financing round from investors including Commonwealth Capital Ventures and Pilot House Ventures, according to PE... Read more »

• IRobot Dives into Underwater Robotics, American Superconductor Inks a Supersized Wind Power Deal, BCBSMA Insures Members’ Google Health, & More Deals News

  Deal-making took New England tech firms all over the map last week. Let’s start with Beijing.

  —Akamai Technologies (NASDAQ: AKAM) of Cambridge, MA, announced it will partner with New York’s... Read more »

• Vertex Moves Hepatitis Drug Forward, Merrimack Rakes in $60M, Biogen and Icahn Trade Barbs, & More Life Sciences News

  Much of the week’s life sciences news was dominated by the bickering of Biogen Idec and billionaire investor Carl Icahn. A few other interesting things happened, though. Those first:

  —Merrimack Pharmaceuticals... Read more »

• Turbine Confirms $40M Round, Nuance Prices Secondary Offering, Sirtris Completes GSK Deal, & More Deals News

  New England software firms had a busy week, it seems, and there were a couple of key biotech deals too. Here’s the rundown:

  —Boston-based OpenAir, a provider of Web-based services automation... Read more »

• Vertex Cashes Out HIV Drugs, FDA Smiles on Infinity and Frowns on Indevus, Alnylam Makes Cross-Border Investment, & More Life Sciences News

  Boston-area life sciences firms had mixed success navigating regulatory waters this week. Here’s the skinny on that and the rest of the week’s biomedical news.

  —Vertex Pharmaceuticals (NASDAQ: VRTX) sold... Read more »

• $400M Contract for Foster-Miller, 65K Order for OLPC, $1B In, $5M Out for Alnylam, & More Deals News

  Sheesh, maybe it was the sheer volume of the last week’s deals that made the equipment at our Web hosting company explode. Check it out:

  —The U.S. military awarded Foster-Miller... Read more »

• Takeda and Alnylam Join Forces, Carl Icahn Makes His Case, New England Biotech is Hot (Duh), & More Life Sciences News

  Japan’s Takeda took another bite out of Boston-area biotech this week, while Ernst & Young’s numbers showed just how juicy that apple is. Here’s more on that, and the rest of... Read more »

• Evergreen Rakes in the Green, NxStage Plans Two-Stage Deal, Atlas Places Big Bet on MicroRNA, & More Deals News

  Smaller deals were the rule last week, but this first one marked an exception.

  —Evergreen Solar (NASDAQ: ESLR) of Marlboro, MA, inked about $1 billion worth of new long-term sales... Read more »

• Shares of Evergreen Solar Shine After $1 Billion Contract News

  Evergreen Solar (NASDAQ: ESLR), a solar-power-product manufacturer that Xconomist Bill Aulet calls one of the poster children for clean-energy success, got a nice bump on the stock market this... Read more »

• A Diagnostics Non-Profit Takes the 100K Prize, Greenfuel Gets a $13.9M Bump for Algae Bioreactors, Beth Israel Teams With Google, and More Life Sciences News

  For-profit firms are the bread and butter of the New England biotech startup scene, but it was nice to see a new non-profit getting a little love last week. Here’s that... Read more »

• OLPC Teams With Microsoft, Wired Bonds with Ars Technica, Greenfuel Gets More Green, & More Deals News

  There was a steady flow of Boston-area deals last week—not to mention a couple of nice ones for our fellow tech-media companies.

  —The One Laptop Per Child Foundation forged an agreement... Read more »

• Introducing Greg. He Rocks.

  Astute readers will have noticed a new byline cropping up on Xconomy for the last week or so. It’s our new Seattle editor, Greg Huang. Seattle? Yeah, that’s what I said—more... Read more »

• OmniGuide Pulls Off Planned $25M Financing Round

  Yoel Fink was a hard man to get a hold of back in March when Neil interviewed the OmniGuide CEO. Fink explained at the time that he was busy courting potential... Read more »

• BSX Meets With Much Approval, Biogen and Icahn Set the (Showdown) Date, Fate’s Fate Revealed, Win Free Stuff, & More Life Sciences News

  Each week I round up the latest news from the New England life sciences cluster, but this week I also want to offer you, gentle reader, the opportunity to share your... Read more »

• Elixir Pulls IPO, Mascoma Runs With Marathon, InnoCentive Gets an Incentive, Novartis Ups Alnylam Stake, & More Deals News

  New England’s corporate attorneys must have been working overtime, because the last week saw an unusual amount of deals activity—particularly in public and private stock offerings.

  —Citing market conditions, Elixir Pharmaceuticals... Read more »

• With An Offering Worth Up to $80.5 Million, Gomez Could Help Revive the Moribund IPO Market

  “IPOs: Back from the Dead?” BusinessWeek asked this morning—and, as if to answer, Lexington, MA-based Gomez filed for an offering worth up to $80.5 million. (And if that combination of... Read more »

• Concert Strikes a Chord With Investors, Abiomed Scores a Win with Medicare, Epix Snags $7.5M from GSK, & More Life Sciences News

  Is it Wednesday again already? Must be time for some life sciences news…

  —Lexington, MA’s Concert Pharmaceuticals raised $37 million in one of this year’s biggest Series C rounds in New... Read more »

• Mascoma Teams with GM, Moldflow Melds with Autodesk, Concert Scores Some Heavy-Duty Cash, & More Deals News

  Last week saw several very large financing deals. Perhaps those depressing Q1 numbers gave investors a little kick in the rear?

  —Concert Pharmaceuticals of Lexington, MA, raised a hefty $37 million... Read more »